Loading screener state…
Loading screener state…
| Symbol | Rank | revenue cagr 8y | roce proxy streak 8y 12pct | de ratio(×) | Why it qualified |
|---|---|---|---|---|---|
| LTM | 1 | 23.9 | True | 0.00 | Revenue CAGR (8Y): 23.89%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| 506854 | 2 | 18.1 | True | 0.25 | Revenue CAGR (8Y): 18.11%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.25 |
| ECLERX | 3 | 16.3 | True | 0.00 | Revenue CAGR (8Y): 16.30%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| AJANTPHARM | 4 | 15.0 | True | 0.05 | Revenue CAGR (8Y): 14.96%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.05 |
| TATAELXSI | 5 | 13.0 | True | 0.00 | Revenue CAGR (8Y): 13.00%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| SWARAJENG | 6 | 12.7 | True | 0.00 | Revenue CAGR (8Y): 12.65%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| ESABINDIA | 7 | 12.3 | True | 0.00 | Revenue CAGR (8Y): 12.25%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| FINEORG | 8 | 12.1 | True | 0.02 | Revenue CAGR (8Y): 12.15%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.02 |
| LTTS | 9 | 11.7 | True | 0.00 | Revenue CAGR (8Y): 11.67%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| INFY | 10 | 11.6 | True | 0.00 | Revenue CAGR (8Y): 11.64%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| HCLTECH | 11 | 11.6 | True | 0.00 | Revenue CAGR (8Y): 11.58%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| CRISIL | 12 | 11.1 | True | 0.00 | Revenue CAGR (8Y): 11.08%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
| PIDILITIND | 13 | 10.9 | True | 0.01 | Revenue CAGR (8Y): 10.90%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.01 |
| SUPREMEIND | 14 | 10.4 | True | 0.00 | Revenue CAGR (8Y): 10.40%PAT/Assets ≥ 12%, 8 Years: yesDebt/Equity: 0.00 |
Educational analysis only. Not investment advice. Scores reflect verified data as of the last nightly compute.